Dutch Organ-on-Chip Innovations Spotlighted at Swiss Biotech Days
Basel, Friday, 25 April 2025.
Health~Holland to showcase organ-on-chip advancements at Swiss Biotech Days, merging Dutch and Swiss biotech expertise and strengthening collaboration in cutting-edge innovations.
Strategic Showcase in Basel
The Netherlands is set to demonstrate its leadership in healthtech innovation at the Swiss Biotech Days, taking place on May 5-6, 2025, in Basel, Switzerland. Health~Holland will maintain a prominent presence at the event, offering a platform for showcasing Dutch expertise in organ-on-chip technology [1]. This strategic participation aligns with the Netherlands’ broader ambition to establish itself as a global biotechnology leader by 2040, supported by a substantial €1.3 billion government investment [2].
Networking and Collaboration Opportunities
The event features extensive networking opportunities, including an exclusive side visit on May 7, 2025, designed to provide deeper insights into the Swiss biotech market [1]. Dutch startups have been offered a unique opportunity to participate in pitch sessions, presenting their innovations to potential investors and partners. The registration deadline for this prestigious event is set for April 11, 2025, with Health~Holland offering special discount codes to facilitate Dutch participation [1].
Broader European Integration
The collaboration extends beyond the Swiss Biotech Days, with several related events scheduled throughout 2025, including the Organ-on-Chip meeting in Heidelberg on April 29 and the EUROoCs-MPS in Brussels from June 9-13 [1]. These gatherings form part of a comprehensive European initiative to advance healthcare innovation, supported by organizations such as the Innovative Health Initiative, an EU public-private partnership funding health research and innovation [3].
Future Developments and Market Impact
A detailed market study examining Netherlands-Switzerland collaboration is currently underway, with findings to be consolidated into a strategic roadmap [1]. This initiative demonstrates the growing importance of international partnerships in advancing biotechnology innovations, particularly in the organ-on-chip sector, which represents a significant advancement in medical research and drug development [GPT].